A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 154 participants.
Also called NCT05355402
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 154 participants
- Sponsor
- Registry
-
NCT05355402
-
- Other papers using this trial's data
- Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada
- Registry status
- Completed
Technical summary
Registry record NCT05355402. Randomized; quadruple masking; primary purpose treatment. Start 2022-05-09 (actual); primary completion 2023-03-22 (actual). Results posted on 2026-04-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia
- Condition
- Hypertriglyceridemia
- Condition
- Atherosclerotic Cardiovascular Disease
- Condition
- Severe Hypertriglyceridemia
- Intervention (Drug)
- Olezarsen
- Intervention (Drug)
- Placebo
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
Record details
- Record id
cardio:ct-nct05355402- Content hash
e5fa9d949111472e98f3e8e0d8ddf339dee377e538276c5a057014d82d48aaf3